Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 25, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0001595248 | ||
Entity Registrant Name | Genprex, Inc. | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Transition Report | false | ||
Entity File Number | 001-38244 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 90-0772347 | ||
Entity Address, Address Line One | 3300 Bee Cave Road #650-227 | ||
Entity Address, City or Town | Austin | ||
Entity Address, State or Province | TX | ||
Entity Address, Postal Zip Code | 78746 | ||
City Area Code | 877 | ||
Local Phone Number | 774-4679 | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
Trading Symbol | GNPX | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 48,500,000 | ||
Entity Common Stock, Shares Outstanding | 1,910,441 | ||
Auditor Name | WithumSmith+Brown, PC | ||
Auditor Location | East Brunswick, New Jersey | ||
Auditor Firm ID | 100 |
Balance Sheets
Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 6,737,629 | $ 20,954,069 |
Accounts receivable | 0 | 34,852 |
Prepaid expenses and other | 794,138 | 484,224 |
Total current assets | 7,531,767 | 21,473,145 |
Property and equipment, net | 7,859 | 23,032 |
Other assets: | ||
Security deposits | 10,000 | 21,818 |
Research and development supplies | 2,347,488 | 2,864,937 |
Intellectual property, net | 773,478 | 702,095 |
Total other assets | 3,130,966 | 3,588,850 |
Total assets | 10,670,592 | 25,085,027 |
Current liabilities: | ||
Accounts payables | 1,397,610 | 442,925 |
Other current liabilities | 1,856,598 | 2,367,362 |
Total current liabilities | 3,254,208 | 2,810,287 |
Stockholders' equity: | ||
Common stock $0.001 par value: 200,000,000 shares authorized; 1,485,902 and 1,202,677 shares issued and outstanding, respectively | 1,486 | 1,203 |
Additional paid-in capital | 141,103,178 | 125,101,356 |
Accumulated deficit | (133,688,280) | (102,827,819) |
Total stockholders' equity | 7,416,384 | 22,274,740 |
Total liabilities and stockholders' equity | $ 10,670,592 | $ 25,085,027 |
Balance Sheets (Parentheticals)
Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 1,485,902 | 1,202,677 |
Common stock, shares outstanding (in shares) | 1,485,902 | 1,202,677 |
Statements of Operations
Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | $ 0 | $ 0 |
Cost and expenses: | ||
Depreciation | 15,004 | 25,575 |
Research and development | 17,616,605 | 11,510,074 |
General and administrative | 13,443,961 | 12,295,070 |
Total costs and expenses | 31,075,570 | 23,830,719 |
Operating loss | (31,075,570) | (23,830,719) |
Interest income | 215,109 | 90,098 |
Net loss | $ (30,860,461) | $ (23,740,621) |
Net loss per share — basic and diluted (in dollars per share) | $ (22.56) | $ (19.8) |
Weighted average number of common shares — basic and diluted (in shares) | 1,367,747 | 1,198,837 |
Statements of Changes in Stockh
Statements of Changes in Stockholders' Equity - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2021 | 1,196,893 | |||
Balance at Dec. 31, 2021 | $ 1,197 | $ 120,362,992 | $ (79,087,198) | $ 41,276,991 |
Issuance of common stock for cash (in shares) | 3,023 | |||
Issuance of common stock for cash | $ 3 | 6,423 | 0 | 6,426 |
Issuance of common stock for services (in shares) | 2,761 | |||
Issuance of common stock for services | $ 3 | 163,229 | 0 | 163,232 |
Share-based compensation | 0 | 4,568,712 | 0 | 4,568,712 |
Net loss | $ 0 | 0 | (23,740,621) | (23,740,621) |
Balance (in shares) at Dec. 31, 2022 | 1,202,677 | |||
Balance at Dec. 31, 2022 | $ 1,203 | 125,101,356 | (102,827,819) | 22,274,740 |
Issuance of common stock for services (in shares) | 500 | |||
Issuance of common stock for services | $ 1 | 19,009 | 0 | 19,010 |
Share-based compensation | 0 | 5,389,718 | 0 | 5,389,718 |
Net loss | $ 0 | 0 | (30,860,461) | (30,860,461) |
Issuance of common stock and warrants for cash net of issuance costs (in shares) | 282,725 | |||
Issuance of common stock and warrants for cash net of issuance costs | $ 282 | 10,593,095 | 0 | 10,593,377 |
Balance (in shares) at Dec. 31, 2023 | 1,485,902 | |||
Balance at Dec. 31, 2023 | $ 1,486 | $ 141,103,178 | $ (133,688,280) | $ 7,416,384 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash flows from operating activities: | ||
Net loss | $ (30,860,461) | $ (23,740,621) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 15,004 | 25,575 |
Share-based compensation | 5,408,728 | 4,731,944 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 34,852 | (34,852) |
Prepaid expenses and other | (309,914) | 27,125 |
Research and development supplies | 517,449 | 157,465 |
Deposits | 11,818 | (13,127) |
Accounts payable | 954,686 | (530,269) |
Other current liabilities | (510,765) | 1,755,262 |
Net cash used in operating activities | (24,738,603) | (17,621,498) |
Cash flows from investing activities: | ||
Reductions to property and equipment | 169 | 0 |
Additions to intellectual property | (71,383) | (59,735) |
Net cash used in investing activities | (71,214) | (59,735) |
Cash flows from financing activities: | ||
Net proceeds from issuances of common stock | 10,593,377 | 6,426 |
Net cash provided by financing activities | 10,593,377 | 6,426 |
Net decrease in cash | (14,216,440) | (17,674,807) |
Cash and cash equivalents, beginning of year | 20,954,069 | 38,628,876 |
Cash and cash equivalents, end of year | $ 6,737,629 | $ 20,954,069 |
Insider Trading Arrangements
Insider Trading Arrangements | 12 Months Ended |
Dec. 31, 2023 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 9B. Rule 10b5 1 10b5 1 During the fiscal quarter ended December 31, 2023, none 16a 1 10b5 1 10b5 1 408 |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Note 1 - Description of Busines
Note 1 - Description of Business and Basis of Presentation | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1 Genprex, Inc. (“Genprex” or the “Company”), incorporated in Delaware in April 2008, 1 may 2 Oncology Platform Genprex’s lead oncology drug candidate, REQORSA® Immunogene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX- 001, Acclaim – 1: 2a 1/2 1 1 May 2023 1 1 1 1 2a no 1 2 “RP2D” 0.12 1 2a first January 2024. 2a 66 19 19 2a 2024, 2025. 1 Acclaim – 2: 1 1/2 2 2 0.06 first 2 2 0.09 0.12 March 2023, 2 second 2024. 2a RP2D. 2 The expansion portion of both the Acclaim- 1 2 2 RP2D 2 Acclaim – 3: 1 1/2 3 3 not January 2024, 1 3 1 second 2024 2 3 second 2024. June 2023, 3 not August 2023, The TUSC2 one 3 August 2022, three TUSC2 Diabetes Gene Therapy In diabetes, the Company has exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of Pittsburgh”) multiple technologies relating to the development of a gene therapy product for each of Type 1 2 1 2 Pdx1 002 1 2 002 1 may 002 2 003 not December 2023, first 2024 October 2023, one August 2022 002 2 July 2023. Pdx1 1 2 7 10 February 2023, 1 002 16th 2023 April 2023, 1 2023 1 Capital Requirements, Liquidity and Going Concern Considerations The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, the Company has sustained substantial losses from operations since inception and has no The Company recognizes that it must obtain additional capital resources to successfully commercialize its product candidates. To date, Genprex has received funding in the form of equity and debt, and the Company plans to seek additional funding in the future. However, no not may not Genprex believes that its current cash and cash equivalents will be sufficient to fund expenditure requirements for its necessary operations and expected clinical trial activities into the third 2024. may no As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern. These financial statements do not |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2 Genprex’s financial statements have been prepared in accordance with US GAAP. Accordingly, they do not not not Reverse Stock Split On February 2, 2024, 1 not 4 Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no December 31, 2022 Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Genprex considers all highly liquid short-term investments with an initial maturity of three $250,000 December 31, 2023 2022 Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 632,323 unexercised options granted by the Company’s board of directors and warrants to purchase shares of common stock, and (ii) 51,862 unvested restricted stock units to purchase shares of common stock granted by the Company’s board of directors as of December 31, 2023 Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, money-market savings account, accounts receivable, and accounts payables approximate fair value because of the immediate or short-term maturity of these financial instruments. Property and Equipment Furniture and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Materials Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company's preclinical and Phase 1/2 Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have no Research and development supplies purchased and capitalized for future use were $2,347,488 and $2,864,937 at December 31, 2023 2022 Intellectual Property Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex that it believes contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining intellectual property protection, such as patent applications and filing fees associated with and patent protection, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. Accounting for Stock-Based Compensation Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognize the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Long-Lived Assets Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023 2022 no Recent Accounting Developments Accounting pronouncements issued but not December 31, 2023 not |
Note 3 - Intellectual Property
Note 3 - Intellectual Property | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | Note 3 As of December 31, 2023, University of Pittsburgh On February 11, 2020, 1 2 first August 17, 2022, November 3, 2022, 1 On November 22, 2022, 1 On December 29, 2022, Pdx1 2 On July 14, 2023, 1 2 Pdx1 The University of Texas MD Anderson Cancer Center On May 4, 2020, 7 |
Note 4 - Equity
Note 4 - Equity | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | Note 4 Reverse Stock Split On February 2, 2024, 1 not Registered Direct Offerings On March 1, 2023, 5 may On July 21, 2023, July 18, 2028. may See “Note 9 March 2024 March 2024 At-The Market Offering On November 18, 2022, may “2022 3 No. 333 239134 December 31, 2023 2022 December 12, 2023, 2022 December 13, 2023. On December 13, 2023, “2023 may may 3 No. 333 271386 April 21, 2023, June 9, 2023. three December 31, 2023, not 2023 See “Note 9 2023 2023 December 31, 2023 881,946 Stock Issuances During the year ended December 31, 2023 During the year ended December 31, 2022 Preferred Stock Genprex is authorized to issue 10,000,000 shares of preferred stock at a par value of $0.001 per share, none December 31, 2023 Common Stock Genprex is authorized to issue 200,000,000 shares of common stock at a par value of $0.001 per share, all of which is voting common stock. There were 1,485,902 shares of common stock outstanding at December 31, 2023 Common Stock Purchase Warrants Common stock purchase warrant activity for the years ended December 31, 2023 2022 2023 2022 Number of Weighted Average Number of Weighted Average Warrants Exercise Price Warrants Exercise Price Outstanding at January 1, 53,695 $ 172.81 55,121 $ 175.65 Warrants issued 296,273 38.75 2,575 61.55 Warrants exercised — — 342 20.00 Warrants cancelled or expired 3,528 209.77 3,659 151.66 Outstanding at December 31, 346,440 $ 57.79 53,695 $ 172.81 Exercisable at December 31, 340,585 $ 57.36 47,548 $ 183.42 During the year ended December 31, 2023 March 1, 2023, July 21, 2023, July 21, 2023, December 31, 2023 March 2018, December 31, 2023 During the year ended December 31, 2022 November 2019 December 31, 2022 As of December 31, 2023 12 five December 31, 2023 December 31, 2022 December 31, 2023 Twelve Months Ended December 31, 2023 Expected term (in years): 2.5 - 3.0 Risk-free rate: 5.33% - 5.52% Volatility: 83.42% Dividend yield: 0% 2018 Genprex’s board of directors and stockholders have approved and adopted the Company’s 2018 “2018 April 3, 2018. 2018 422 1986, may may The number of shares of common stock reserved for issuance under the 2018 January 1 January 1, 2019 December 31 2018 January 1, 2023 2022, 2018 December 31, 2023 2018 December 31, 2023 2018 2018 Genprex’s board of directors and stockholders approved and adopted the Company’s 2018 April 3, 2018. not may January 1 January 1, 2019, December 31 not January 1, 2023. Stock Options As of December 31, 2023 2018 2021 2023. ten Twelve Months Ended December 31, 2023 Twelve Months Ended December 31, 2022 Expected term (in years): 6.0 10 Risk-free rate: 4.60% – 5.37% 0.07% – 4.77% Volatility: 83.14% - 83.42% 75.98% - 88.38% Dividend yield: 0% 0% During the year ended December 31, 2023 During the year ended December 31, 2022 The weighted average remaining contractual term for the outstanding options at December 31, 2023 2022 Stock option activity for the years ended December 31, 2023 2022 2023 2022 Number of Weighted Average Number of Weighted Average Options Exercise Price Options Exercise Price Outstanding at January 1, 284,377 $ 123.19 214,370 $ 134.14 Options granted 8,251 30.14 74,600 86.45 Options exercised 500 11.92 2,925 0.60 Options expired or cancelled 6,245 104.42 1,668 101.88 Outstanding at December 31, 285,883 $ 121.11 284,377 $ 123.19 Exercisable at December 31, 237,859 $ 124.73 167,957 $ 129.19 Restricted Stock Units A summary of the RSU activity under the 2018 December 31, 2023 no December 31, 2022. 2023 Number of Weighted Average Units Grant Date Fair Value Outstanding at January 1, — $ — Restricted stock units granted 57,119 60.08 Restricted stock units forfeited or cancelled 5,257 66.00 Outstanding at December 31, 51,862 $ 59.48 Share-Based Compensation In the year ended December 31, 2023 December 31, 2023 not three December 31, 2023 As of December 31, 2023 one not may In the year ended December 31, 2022 |
Note 5 - 401(k) Savings Transac
Note 5 - 401(k) Savings Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Defined Contribution Plan [Text Block] | Note 5 401 Transactions In 2022, 401 “401 401 401 401 December 31, 2023 2022 |
Note 6 - Related Party Transact
Note 6 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 6 Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company formed by Rodney Varner, Genprex’s President, Chief Executive Officer and Chairman of the Board and IRI’s sole officer. IRI is owned by trusts of which Mr. Varner’s descendants are the sole beneficiaries. In April 2009, August 2012, 2011 7 |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 7 Commitments MD Anderson In July 2018, two May 2022. August 2022, three December 31, 2023 In 2011, 1994 On March 3, 2021, May 4, 2020, six one TUSC2 TUSC2 five six one five December 31, 2023 National Institutes of Health Genprex has a royalty obligation to the National Institutes of Health (“NIH”) to be paid upon the Company’s receipt of FDA approval using NIH technology. The $240,000 contingent obligation which increases annually by $20,000 and is $360,000 and $340,000 for the years ended December 31, 2023 2022 University of Pittsburgh Pursuant to an exclusive license agreement dated February 11, 2020 August 17, 2022, November 3, 2022, first three first first 1 20 first December 31, 2023 Pursuant to an exclusive license agreement dated November 22, 2022 first three first first 1 20 first December 31, 2023 Pursuant to an exclusive license agreement dated December 29, 2022 first three first first 2 20 first December 31, 2023 Pursuant to an exclusive license agreement dated July 14, 2023, first second third fourth fourth first first 1 2 20 first December 31, 2023 Contract Development and Manufacturing Organization Genprex entered into a three July 2022, January 2023 March 2023, December 31, 2023 Contingencies From time to time, the Company may not |
Note 8 - Income Taxes
Note 8 - Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 8 Components of income tax benefit for the year ended December 31, 2023 2022 December 31, 2023 December 31, 2022 Current Tax Expense (Benefit): Federal — — State — — Total — — Deferred Tax Expense (Benefit): Federal — — State — — Total — — Total Provision for Income Taxes — — Temporary differences between financial statement carrying amount and tax basis of assets and liabilities that give rise to significant portions of the deferred tax assets and liabilities at December 31, 2023 2022 December 31, 2023 December 31, 2022 Deferred tax assets: Allowance for Doubtful Accounts — — Interest Expense — — Intangible Assets - R&D Expenses 4,710,079 1,986,102 Accrued Expenses 684,699 561,496 Tax Credits 1,434,851 728,701 Stock Compensation Expense 306,906 94,237 Net Operating Losses 16,915,002 14,464,170 Total Deferred Income Tax Assets 24,051,538 17,834,706 Deferred Income Tax Liabilities: Fixed Assets (1,650 ) (4,354 ) Intangible Assets — — Prepaid Expenses (629,136 ) (710,643 ) Lease - Right of Use — — Unrealized Gain/Loss — — Total Deferred Income Tax Liabilities (630,786 ) (714,997 ) Less Valuation Allowance (23,420,752 ) (17,119,710 ) Net Deferred Income Tax Asset — — At December 31, 2023 2022 In assessing the ability to realize the deferred tax assets, management considers whether it is more likely than not not December 31, 2023 2022 The Company has federal research and development (“R&D”) credit carryforwards of $1.4 million which will begin to expire in 2037. Effective January 1, 2009 740 10, No. 48, “FIN48” two first not second not 50 |
Note 9 - Subsequent Events
Note 9 - Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 9 Reserves of 2018 2018 On January 1, 2024, 2018 March 14, 2024, no 2024 no Share Issuances On January 2, 2024, January 3, 2024, March 14, 2024, 2023 From January 1, 2024 10 2023 Reverse Stock Split At Genprex’s special meeting of stockholders held on December 14, 2023, not 1 10 not 1 50, January 19, 2024, 1 February 2, 2024. not 10 Departure of a Named Executive Officer Effective as of February 4, 2024, March 2024 On March 21, 2024, “March 2024 “March 2024 March 2024 March 2024 March 2024 March 2024 March 2024 may March 2024 March 2023 July 2023, March 1, 2028 July 21, 2028 five |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Reverse Stock Split, Policy [Policy Text Block] | Reverse Stock Split On February 2, 2024, 1 not 4 |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no December 31, 2022 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the Company’s financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents Genprex considers all highly liquid short-term investments with an initial maturity of three $250,000 December 31, 2023 2022 |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock, which includes common stock equivalents consisting of (i) 632,323 unexercised options granted by the Company’s board of directors and warrants to purchase shares of common stock, and (ii) 51,862 unvested restricted stock units to purchase shares of common stock granted by the Company’s board of directors as of December 31, 2023 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, money-market savings account, accounts receivable, and accounts payables approximate fair value because of the immediate or short-term maturity of these financial instruments. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Furniture and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Materials Costs Research and development expenditures consist of costs incurred to conduct research, develop engineering materials for further study, and develop clinical strategies for current and future programs associated with the Company's preclinical and Phase 1/2 Materials acquired to be used in clinical research, that have an alternative future use, are capitalized when the materials are acquired, and included in research and development supplies. These supplies are recognized as expense as they are consumed through use for testing or clinical activities, or have spoiled. The costs of materials that were acquired for a particular research and development activity and have no Research and development supplies purchased and capitalized for future use were $2,347,488 and $2,864,937 at December 31, 2023 2022 |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intellectual Property Intellectual property consists of legal and related costs associated with patents, trademarks, and other proprietary technology and rights developed, acquired, or licensed by Genprex that it believes contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining intellectual property protection, such as patent applications and filing fees associated with and patent protection, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. |
Share-Based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation Genprex uses the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. The Company measures options granted at fair value determined as of the grant date and recognize the expense over the periods in which the options vest or are expected to vest and related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets Genprex reviews long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023 2022 no |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Developments Accounting pronouncements issued but not December 31, 2023 not |
Note 4 - Equity (Tables)
Note 4 - Equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | 2023 2022 Number of Weighted Average Number of Weighted Average Warrants Exercise Price Warrants Exercise Price Outstanding at January 1, 53,695 $ 172.81 55,121 $ 175.65 Warrants issued 296,273 38.75 2,575 61.55 Warrants exercised — — 342 20.00 Warrants cancelled or expired 3,528 209.77 3,659 151.66 Outstanding at December 31, 346,440 $ 57.79 53,695 $ 172.81 Exercisable at December 31, 340,585 $ 57.36 47,548 $ 183.42 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Twelve Months Ended December 31, 2023 Expected term (in years): 2.5 - 3.0 Risk-free rate: 5.33% - 5.52% Volatility: 83.42% Dividend yield: 0% Twelve Months Ended December 31, 2023 Twelve Months Ended December 31, 2022 Expected term (in years): 6.0 10 Risk-free rate: 4.60% – 5.37% 0.07% – 4.77% Volatility: 83.14% - 83.42% 75.98% - 88.38% Dividend yield: 0% 0% |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | 2023 2022 Number of Weighted Average Number of Weighted Average Options Exercise Price Options Exercise Price Outstanding at January 1, 284,377 $ 123.19 214,370 $ 134.14 Options granted 8,251 30.14 74,600 86.45 Options exercised 500 11.92 2,925 0.60 Options expired or cancelled 6,245 104.42 1,668 101.88 Outstanding at December 31, 285,883 $ 121.11 284,377 $ 123.19 Exercisable at December 31, 237,859 $ 124.73 167,957 $ 129.19 |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | 2023 Number of Weighted Average Units Grant Date Fair Value Outstanding at January 1, — $ — Restricted stock units granted 57,119 60.08 Restricted stock units forfeited or cancelled 5,257 66.00 Outstanding at December 31, 51,862 $ 59.48 |
Note 8 - Income Taxes (Tables)
Note 8 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | December 31, 2023 December 31, 2022 Current Tax Expense (Benefit): Federal — — State — — Total — — Deferred Tax Expense (Benefit): Federal — — State — — Total — — Total Provision for Income Taxes — — |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2023 December 31, 2022 Deferred tax assets: Allowance for Doubtful Accounts — — Interest Expense — — Intangible Assets - R&D Expenses 4,710,079 1,986,102 Accrued Expenses 684,699 561,496 Tax Credits 1,434,851 728,701 Stock Compensation Expense 306,906 94,237 Net Operating Losses 16,915,002 14,464,170 Total Deferred Income Tax Assets 24,051,538 17,834,706 Deferred Income Tax Liabilities: Fixed Assets (1,650 ) (4,354 ) Intangible Assets — — Prepaid Expenses (629,136 ) (710,643 ) Lease - Right of Use — — Unrealized Gain/Loss — — Total Deferred Income Tax Liabilities (630,786 ) (714,997 ) Less Valuation Allowance (23,420,752 ) (17,119,710 ) Net Deferred Income Tax Asset — — |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) | 12 Months Ended | |||
Feb. 02, 2024 | Jan. 19, 2024 | Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) | |
Cash, Uninsured Amount | $ 6,490,117 | $ 20,679,538 | ||
Research and Development Assets, Current | 2,347,488 | 2,864,937 | ||
Impairment, Long-Lived Asset, Held-for-Use | $ 0 | $ 0 | ||
Minimum [Member] | ||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |||
Maximum [Member] | ||||
Property, Plant and Equipment, Useful Life (Year) | 5 years | |||
Share-Based Payment Arrangement, Option [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 632,323 | |||
Restricted Stock Units (RSUs) [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 51,862 | |||
Subsequent Event [Member] | Reverse Stock Split [Member] | ||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 40 | 40 |
Note 3 - Intellectual Property
Note 3 - Intellectual Property (Details Textual) | 12 Months Ended |
Dec. 31, 2023 | |
Number of Granted Patents | 21 |
Number of Pending Patent Applications | 23 |
Note 4 - Equity (Details Textua
Note 4 - Equity (Details Textual) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||
Mar. 21, 2024 USD ($) $ / shares shares | Feb. 02, 2024 | Jan. 19, 2024 | Jan. 02, 2024 shares | Jan. 01, 2024 shares | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 13, 2023 | Jul. 21, 2023 USD ($) $ / shares shares | Mar. 01, 2023 USD ($) $ / shares shares | Jan. 01, 2023 shares | Nov. 18, 2022 USD ($) | Jan. 01, 2022 shares | Mar. 31, 2024 USD ($) | Mar. 28, 2024 USD ($) shares | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 $ / shares shares | Apr. 03, 2018 shares | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 346,440 | 346,440 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 57.79 | $ 57.79 | $ 172.81 | $ 175.65 | ||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 10,593,377 | $ 6,426 | ||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 19,010 | $ 163,232 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 500 | 2,925 | ||||||||||||||||
Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares) | 342 | |||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | ||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | ||||||||||||||||
Preferred Stock, Shares Outstanding (in shares) | 0 | 0 | ||||||||||||||||
Common Stock, Shares Authorized (in shares) | 200,000,000 | 200,000,000 | 200,000,000 | |||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||
Common Stock, Shares, Outstanding (in shares) | 1,485,902 | 1,485,902 | 1,202,677 | |||||||||||||||
Class of Warrant or Right, Issued in Period (in shares) | 296,273 | 2,575 | ||||||||||||||||
Class of Warrant or Right, Cancelled During Period (in shares) | 3,528 | 3,659 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 285,883 | 285,883 | 284,377 | 214,370 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 121.11 | $ 121.11 | $ 123.19 | $ 134.14 | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 8,251 | 74,600 | ||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 30.14 | $ 86.45 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period (in shares) | 6,245 | 1,668 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 104.42 | $ 101.88 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 6 years 1 month 17 days | 7 years 29 days | ||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 346,440 | 346,440 | 53,695 | 55,121 | ||||||||||||||
Options and Warrants [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 5,400,000 | |||||||||||||||||
Options and Warrants [Member] | General and Administrative Expense [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | 4,400,000 | |||||||||||||||||
Options and Warrants [Member] | Research and Development Expense [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | 1,000,000 | |||||||||||||||||
Time-Based Stock Option Awards, RSUs, and Warrants [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ | $ 4,700,000 | $ 4,700,000 | ||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 years | |||||||||||||||||
Time-Based Stock Option Awards, RSUs, and Warrants [Member] | Related to General and Administrative Expense [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ | 3,800,000 | $ 3,800,000 | ||||||||||||||||
Time-Based Stock Option Awards, RSUs, and Warrants [Member] | Related to Research and Development Expense [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ | $ 900,000 | $ 900,000 | ||||||||||||||||
Performance Shares [Member] | ||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 0 | 0 | ||||||||||||||||
Share-Based Payment Arrangement, Option [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 4,700,000 | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $ | $ 4,600,000 | |||||||||||||||||
The 2018 Equity Incentive Plan [Member] | ||||||||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 5% | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 74,294 | 60,132 | 59,843 | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 11,686 | 11,686 | ||||||||||||||||
The 2018 Employee Stock Purchase Plan [Member] | ||||||||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 2% | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 5,202 | |||||||||||||||||
Excluding the 2018 Equity Incentive Plan [Member] | ||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 25,417 | 25,417 | ||||||||||||||||
Scientific Advisory Board Chairman [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 500 | 500 | ||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 19,200 | $ 42,400 | ||||||||||||||||
Consultant [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 1,919 | |||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 99,010 | |||||||||||||||||
Former Board Member [Member] | ||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 11.92 | $ 11.92 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 500 | |||||||||||||||||
Company Executives [Member] | ||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.6 | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 2,925 | |||||||||||||||||
Maximum [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | 288.8 | $ 288.8 | ||||||||||||||||
Warrants or Rights, Fair Value Per Share (in dollars per share) | $ / shares | 185 | $ 185 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 48 months | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | 140 | $ 140 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | 98.84 | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | 60.4 | $ 140 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | 142 | 146.4 | ||||||||||||||||
Minimum [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | 26 | 26 | ||||||||||||||||
Warrants or Rights, Fair Value Per Share (in dollars per share) | $ / shares | 13.85 | $ 13.85 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 12 months | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | 18 | $ 18 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | 12.62 | |||||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | 18 | 50.8 | ||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 50.8 | $ 80 | ||||||||||||||||
Weighted Average [Member] | Time-Based Stock Option Awards, RSUs, and Warrants [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 1 month 13 days | |||||||||||||||||
Warrants Issued with Registered Direct Offering [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 185,644 | 95,239 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 35.4 | $ 44 | ||||||||||||||||
Class of Warrant or Right, Issued in Period (in shares) | 185,644 | 95,239 | ||||||||||||||||
Placement Agent Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 11,140 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 50.5 | |||||||||||||||||
Class of Warrant or Right, Issued in Period (in shares) | 11,140 | |||||||||||||||||
Class of Warrant or Right, Cancelled During Period (in shares) | 960 | |||||||||||||||||
Warrants Issued for Services [Member] | ||||||||||||||||||
Class of Warrant or Right, Issued in Period (in shares) | 4,250 | |||||||||||||||||
Class of Warrant or Right, Cancelled During Period (in shares) | 2,568 | |||||||||||||||||
Warrants Issued for Services [Member] | Maximum [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | 66 | $ 66 | ||||||||||||||||
Warrants Issued for Services [Member] | Minimum [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 26 | $ 26 | ||||||||||||||||
Vesting of Warrants For Service Provider [Member] | ||||||||||||||||||
Share-Based Payment Arrangement, Expense | $ | $ 133,558 | |||||||||||||||||
Warrant For Service Provider [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,250 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 55.2 | |||||||||||||||||
Warrant For Service Provider 2 [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,250 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 59.6 | |||||||||||||||||
Warrant for Services Provided at IPO [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 75 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 200 | |||||||||||||||||
Class of Warrant or Right, Cancelled During Period (in shares) | 257 | |||||||||||||||||
Warrants from Prior Service Providers [Member] | ||||||||||||||||||
Warrants or Rights, Cancelled During Period (in shares) | 3,402 | |||||||||||||||||
Performance-based Warrant [Member] | ||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1 | 1 | ||||||||||||||||
Warrant, Nonvested Award, Cost Not yet Recognized, Amount | $ | $ 300,000 | $ 300,000 | ||||||||||||||||
Registered Direct Offering [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 95,239 | |||||||||||||||||
Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares | $ 42 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 3,600,000 | |||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 400,000 | |||||||||||||||||
July 2023 Registered Direct Offering [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 185,644 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 6,700,000 | |||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 800,000 | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 40.4 | |||||||||||||||||
The 2022 ATM Facility [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,342 | |||||||||||||||||
Brokerage Commissions, Percentage of Gross Proceeds | 3% | |||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 78,355 | |||||||||||||||||
The 2022 ATM Facility [Member] | Maximum [Member] | ||||||||||||||||||
Common Stock, Shares Authorized, Value | $ | $ 50,000,000 | |||||||||||||||||
The 2023 ATM Facility [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 881,946 | |||||||||||||||||
Brokerage Commissions, Percentage of Gross Proceeds | 3% | |||||||||||||||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | ||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 74,294 | |||||||||||||||||
Subsequent Event [Member] | Scientific Advisory Board Chairman [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 125 | |||||||||||||||||
Subsequent Event [Member] | Registered Direct Offering [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 165,000 | |||||||||||||||||
Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares | $ 4.215 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 5.8 | $ 5.8 | ||||||||||||||||
Subsequent Event [Member] | The 2023 ATM Facility [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 158,474 | |||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 881,946 | |||||||||||||||||
Subsequent Event [Member] | Reverse Stock Split [Member] | ||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 40 | 40 |
Note 4 - Equity - Common Stock
Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Outstanding, number of warrants (in shares) | 53,695 | 55,121 |
Outstanding, weighted average exercise price (in dollars per share) | $ 172.81 | $ 175.65 |
Warrants issued, number of warrants (in shares) | 296,273 | 2,575 |
Warrants issued, weighted average exercise price (in dollars per share) | $ 38.75 | $ 61.55 |
Exercised, number of warrants (in shares) | 342 | |
Exercised, weighted average exercise price (in dollars per share) | $ 20 | |
Warrants cancelled or expired, number of warrants (in shares) | 3,528 | 3,659 |
Warrants cancelled or expired, weighted average exercise price (in dollars per share) | $ 209.77 | $ 151.66 |
Outstanding, number of warrants (in shares) | 346,440 | 53,695 |
Outstanding, weighted average exercise price (in dollars per share) | $ 57.79 | $ 172.81 |
Exercisable, number of warrants (in shares) | 340,585 | 47,548 |
Exercisable, weighted average exercise price (in dollars per share) | $ 57.36 | $ 183.42 |
Note 4 - Equity - Assumptions (
Note 4 - Equity - Assumptions (Details) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Volatility: | 83.42% | |
Dividend yield: | 0% | |
Share-Based Payment Arrangement, Option [Member] | ||
Expected term (in years): (Year) | 6 years | 10 years |
Dividend yield: | 0% | 0% |
Minimum [Member] | ||
Expected term (in years): (Year) | 2 years 6 months | |
Risk-free rate: | 5.33% | |
Minimum [Member] | Share-Based Payment Arrangement, Option [Member] | ||
Risk-free rate: | 4.60% | 0.07% |
Volatility: | 83.14% | 75.98% |
Maximum [Member] | ||
Expected term (in years): (Year) | 3 years | |
Risk-free rate: | 5.52% | |
Maximum [Member] | Share-Based Payment Arrangement, Option [Member] | ||
Risk-free rate: | 5.37% | 4.77% |
Volatility: | 83.42% | 88.38% |
Note 4 - Equity - Stock Option
Note 4 - Equity - Stock Option Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Outstanding, number of shares (in shares) | 284,377 | 214,370 |
Outstanding, weighted average exercise price (in dollars per share) | $ 123.19 | $ 134.14 |
Options granted, number of shares (in shares) | 8,251 | 74,600 |
Options granted, weighted average exercise price (in dollars per share) | $ 30.14 | $ 86.45 |
Options exercised, number of shares (in shares) | 500 | 2,925 |
Options exercised, weighted average exercise price (in dollars per share) | $ 11.92 | $ 0.6 |
Options expired or cancelled, number of shares (in shares) | 6,245 | 1,668 |
Options expired or cancelled, weighted average exercise price (in dollars per share) | $ 104.42 | $ 101.88 |
Outstanding, number of shares (in shares) | 285,883 | 284,377 |
Outstanding, weighted average exercise price (in dollars per share) | $ 121.11 | $ 123.19 |
Exercisable, number of shares (in shares) | 237,859 | 167,957 |
Exercisable, weighted average exercise price (in dollars per share) | $ 124.73 | $ 129.19 |
Note 4 - Equity - Restricted St
Note 4 - Equity - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Outstanding, shares (in shares) | shares | |
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares | |
Restricted stock units granted, shares (in shares) | shares | 57,119 |
Restricted stock units granted, weighted average grant date fair value (in dollars per share) | $ / shares | $ 60.08 |
Restricted stock units forfeited or cancelled (in shares) | shares | 5,257 |
Restricted stock units forfeited or cancelled (in dollars per share) | $ / shares | $ 66 |
Outstanding, shares (in shares) | shares | 51,862 |
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares | $ 59.48 |
Note 5 - 401(k) Savings Trans_2
Note 5 - 401(k) Savings Transactions (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Defined Contribution Plan, Cost | $ 141,564 | $ 74,281 |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||
Sep. 30, 2022 | Jul. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2023 | Dec. 31, 2009 | Jul. 14, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Dec. 29, 2022 | Nov. 22, 2022 | Mar. 03, 2021 | Feb. 11, 2020 | |
License Agreement Terms [Member] | ||||||||||||
Contract Payments Incurred and Paid | $ 320,000 | |||||||||||
License Agreement Milestone Payment | $ 6,150,000 | |||||||||||
National Institute of Health [Member] | ||||||||||||
Royalty on Sales, Percentage | 1% | |||||||||||
Royalty Term (Year) | 21 years | |||||||||||
Royalty Payment, Annual Minimum | $ 20,000 | |||||||||||
Payment for Contingent Consideration Liability, Operating Activities | $ 240,000 | |||||||||||
Contingent Payments Annual Increase | $ 20,000 | |||||||||||
Other Commitment | 360,000 | $ 340,000 | ||||||||||
Research Agreement [Member] | MD Anderson [Member] | ||||||||||||
Long Term Contract, Estimated Cost | $ 2,900,000 | $ 2,000,000 | ||||||||||
Contract Payments Incurred and Paid | 1.2 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | ||||||||||||
Licensing Fee, Amount | $ 25,000 | |||||||||||
Annual Maintenance Fee, First Three Years, Amount | 25,000 | |||||||||||
Annual Maintenance Fee, After Year Three, Amount | 40,000 | |||||||||||
Annual Royalty Payment Per Year, Minimum | $ 250,000 | |||||||||||
Share of Non-Royalty Sublicense Income, Percent | 20% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member] | ||||||||||||
Contract Payments Incurred and Paid | 110,000 | |||||||||||
Milestone Payment | $ 3,975,000 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member] | ||||||||||||
Contract Payments Incurred and Paid | 50,000 | |||||||||||
Licensing Fee, Amount | 25,000 | $ 25,000 | ||||||||||
Annual Maintenance Fee, First Three Years, Amount | 25,000 | |||||||||||
Annual Maintenance Fee, After Year Three, Amount | 40,000 | |||||||||||
Annual Royalty Payment Per Year, Minimum | $ 250,000 | |||||||||||
Share of Non-Royalty Sublicense Income, Percent | 20% | |||||||||||
Milestone Payment | $ 3,975,000 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member] | ||||||||||||
Contract Payments Incurred and Paid | 25,000 | |||||||||||
Licensing Fee, Amount | 25,000 | |||||||||||
Annual Maintenance Fee, First Three Years, Amount | $ 25,000 | |||||||||||
Annual Maintenance Fee, After Year Three, Amount | 40,000 | |||||||||||
Annual Royalty Payment Per Year, Minimum | $ 250,000 | |||||||||||
Share of Non-Royalty Sublicense Income, Percent | 20% | |||||||||||
Milestone Payment | $ 3,975,000 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member] | ||||||||||||
Contract Payments Incurred and Paid | 25,000 | |||||||||||
Annual Royalty Payment Per Year, Minimum | $ 250,000 | |||||||||||
Share of Non-Royalty Sublicense Income, Percent | 20% | |||||||||||
Milestone Payment | $ 4,225,000 | |||||||||||
Annual Maintenance Fee, First Year, Amount | 25,000 | |||||||||||
Annual Maintenance Fee, Second and Third Year, Amount | 50,000 | |||||||||||
Annual Maintenance Fee, Fourth Year, Amount | $ 100,000 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 1.50% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 1.50% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 1.50% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 1.50% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 3% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 Diabetes [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 3% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 2 Diabetes [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 3% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 3% | |||||||||||
Development and Manufacturing of GMP Grade Materials [Member] | ||||||||||||
Contract Payments Incurred and Paid | $ 2,600,000 | |||||||||||
Development Services Agreement, Expected Total Project Cost | $ 4,500,000 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred Tax Assets, Valuation Allowance | $ 23,420,752 | $ 17,119,710 |
Research Tax Credit Carryforward [Member] | Expiration, 2037 [Member] | ||
Tax Credit Carryforward, Amount | 1,400,000 | |
Domestic Tax Authority [Member] | ||
Operating Loss Carryforwards | $ 80,500,000 | $ 68,900,000 |
Note 8 - Income Taxes - Provisi
Note 8 - Income Taxes - Provision for Income Tax Expense (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Current Tax Expense (Benefit): | ||
Federal, Current | $ 0 | $ 0 |
State, Current | 0 | 0 |
Total, Current | 0 | 0 |
Deferred Tax Expense (Benefit): | ||
Federal, Deferred | 0 | 0 |
State, Deferred | 0 | 0 |
Total, Deferred | 0 | 0 |
Total Provision for Income Taxes | $ 0 | $ 0 |
Note 8 - Income Taxes - Schedul
Note 8 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Allowance for Doubtful Accounts | $ 0 | $ 0 |
Interest Expense | 0 | 0 |
Intangible Assets - R&D Expenses | 4,710,079 | 1,986,102 |
Accrued Expenses | 684,699 | 561,496 |
Tax Credits | 1,434,851 | 728,701 |
Stock Compensation Expense | 306,906 | 94,237 |
Net Operating Losses | 16,915,002 | 14,464,170 |
Total Deferred Income Tax Assets | 24,051,538 | 17,834,706 |
Fixed Assets | (1,650) | (4,354) |
Intangible Assets | 0 | 0 |
Prepaid Expenses | (629,136) | (710,643) |
Lease - Right of Use | 0 | 0 |
Unrealized Gain/Loss | 0 | 0 |
Total Deferred Income Tax Liabilities | (630,786) | (714,997) |
Less Valuation Allowance | (23,420,752) | (17,119,710) |
Net Deferred Income Tax Asset | $ 0 | $ 0 |
Note 9 - Subsequent Events (Det
Note 9 - Subsequent Events (Details Textual) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||
Mar. 21, 2024 USD ($) $ / shares shares | Mar. 14, 2024 shares | Feb. 02, 2024 | Jan. 19, 2024 | Jan. 03, 2024 shares | Jan. 02, 2024 shares | Jan. 01, 2024 shares | Dec. 31, 2023 $ / shares shares | Mar. 01, 2023 USD ($) $ / shares shares | Jan. 01, 2023 shares | Jan. 01, 2022 shares | Mar. 31, 2024 USD ($) | Mar. 28, 2024 USD ($) shares | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Jul. 21, 2023 $ / shares shares | Dec. 31, 2021 $ / shares | |
Proceeds from Issuance of Common Stock | $ | $ 10,593,377 | $ 6,426 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 346,440 | 346,440 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 57.79 | $ 57.79 | $ 172.81 | $ 175.65 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |||||||||||||||
Maximum [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 288.8 | $ 288.8 | |||||||||||||||
Warrants Issued with Registered Direct Offering [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 95,239 | 185,644 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 44 | $ 35.4 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |||||||||||||||
The 2023 ATM Facility [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | ||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 881,946 | ||||||||||||||||
Registered Direct Offering [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 95,239 | ||||||||||||||||
Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares | $ 42 | ||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 3,600,000 | ||||||||||||||||
Scientific Advisory Board Chairman [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 500 | 500 | |||||||||||||||
Subsequent Event [Member] | March 2024 Pre-Funded Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.0001 | ||||||||||||||||
Subsequent Event [Member] | March 2024 Pre-Funded Warrants [Member] | Maximum [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,377,112 | ||||||||||||||||
Subsequent Event [Member] | March 2024 Common Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 4.09 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||
Subsequent Event [Member] | March 2024 Common Warrants [Member] | Maximum [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,542,112 | ||||||||||||||||
Subsequent Event [Member] | March 2024 Pre-Funded Warrant and Common Warrant [Member] | |||||||||||||||||
Class of Warrant or Right, Combined Purchase Price | $ | $ 4.2149 | ||||||||||||||||
Subsequent Event [Member] | Amended Registered Direct Offering [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 4.09 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||
Class of Warrant or Right, Amendment Price Per Warrant (in dollars per share) | $ / shares | $ 0.125 | ||||||||||||||||
Subsequent Event [Member] | Amended Registered Direct Offering [Member] | Maximum [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 194,248 | ||||||||||||||||
Subsequent Event [Member] | Reverse Stock Split [Member] | |||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 40 | 40 | |||||||||||||||
Subsequent Event [Member] | The 2023 ATM Facility [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 158,474 | ||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 881,946 | ||||||||||||||||
Subsequent Event [Member] | Registered Direct Offering [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 165,000 | ||||||||||||||||
Equity Offering, Combined Purchase Price (in dollars per share) | $ / shares | $ 4.215 | ||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ | $ 5.8 | $ 5.8 | |||||||||||||||
Subsequent Event [Member] | Scientific Advisory Board Chairman [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 125 | ||||||||||||||||
Subsequent Event [Member] | Service Providers [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 30,000 | 6,250 | |||||||||||||||
The 2018 Equity Incentive Plan [Member] | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 74,294 | 60,132 | 59,843 | ||||||||||||||
The 2018 Equity Incentive Plan [Member] | Subsequent Event [Member] | |||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 74,294 |